{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced%2FMetastatic&page=34", "query": { "condition": "Advanced/Metastatic", "page": 34 }, "page_size": 10 }, "pagination": { "page": 34, "page_size": 10, "total_count": 3818, "total_pages": 382, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced%2FMetastatic&page=35&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced%2FMetastatic&page=33&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T02:03:51.431Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04396626", "title": "HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 975, "start_date": "2019-11-18", "completion_date": "2020-05-31", "has_results": true, "last_update_posted_date": "2023-04-27", "last_synced_at": "2026-10-31T02:03:51.431Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04396626" }, { "nct_id": "NCT00720304", "title": "Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "fluorescence in situ hybridization", "type": "GENETIC" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "immunoenzyme technique", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "intensity-modulated radiation therapy", "type": "RADIATION" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2007-11-19", "completion_date": "2015-11-13", "has_results": true, "last_update_posted_date": "2024-08-22", "last_synced_at": "2026-10-31T02:03:51.431Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00720304" }, { "nct_id": "NCT00704158", "title": "Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "CR011-vcMMAE", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CuraGen Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 42, "start_date": "2008-06", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2015-02-19", "last_synced_at": "2026-10-31T02:03:51.431Z", "location_count": 5, "location_summary": "Fort Myers, Florida • Lake Worth, Florida • Atlanta, Georgia + 2 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Lake Worth", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00704158" }, { "nct_id": "NCT00257426", "title": "Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Cancer" ], "interventions": [ { "name": "octreotide acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2005-07", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2012-02-14", "last_synced_at": "2026-10-31T02:03:51.431Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00257426" }, { "nct_id": "NCT04793958", "title": "Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Colorectal Cancer", "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "MRTX849", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "mFOLFOX6 Regimen", "type": "DRUG" }, { "name": "FOLFIRI Regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 461, "start_date": "2021-06-24", "completion_date": "2026-10-23", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-31T02:03:51.431Z", "location_count": 185, "location_summary": "Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 122 more", "locations": [ { "city": "Alabaster", "state": "Alabama" }, { "city": "Bessemer", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04793958" }, { "nct_id": "NCT05014815", "title": "Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)", "Nonsmall Cell Lung Cancer, Stage IIIB", "Nonsmall Cell Lung Cancer, Stage IV" ], "interventions": [ { "name": "Ociperlimab", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 272, "start_date": "2021-11-16", "completion_date": "2024-09-04", "has_results": true, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-10-31T02:03:51.431Z", "location_count": 11, "location_summary": "Los Angeles, California • Iowa City, Iowa • Las Vegas, Nevada + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "New Hyde Park", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05014815" }, { "nct_id": "NCT04797468", "title": "A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "HLX23", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shanghai Henlius Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-07-18", "completion_date": "2023-01-13", "has_results": false, "last_update_posted_date": "2023-01-17", "last_synced_at": "2026-10-31T02:03:51.431Z", "location_count": 6, "location_summary": "Los Angeles, California • Orange, California • Orange City, Florida + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Orange City", "state": "Florida" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04797468" }, { "nct_id": "NCT00059982", "title": "Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "perifosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2003-07", "completion_date": "2005-08", "has_results": false, "last_update_posted_date": "2013-06-24", "last_synced_at": "2026-10-31T02:03:51.431Z", "location_count": 10, "location_summary": "Urbana, Illinois • South Bend, Indiana • Des Moines, Iowa + 7 more", "locations": [ { "city": "Urbana", "state": "Illinois" }, { "city": "South Bend", "state": "Indiana" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Duluth", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00059982" }, { "nct_id": "NCT07829185", "title": "Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma (PDAC)" ], "interventions": [ { "name": "modified FOLFIRINOX", "type": "DRUG" }, { "name": "Pentamidine 300 MG Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-12", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-31T02:03:51.431Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT07829185" }, { "nct_id": "NCT05118789", "title": "A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Solid Tumor", "Metastatic Solid Tumor" ], "interventions": [ { "name": "Zidesamtinib (NVL-520)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvalent Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 359, "start_date": "2022-01-04", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-31T02:03:51.431Z", "location_count": 20, "location_summary": "Orange, California • Palo Alto, California • Sacramento, California + 15 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05118789" } ] }